GLEN ORDINARIO: Open Payments
NPI 1639465487 · MISSION HILLS, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$781 in 35 payments from 14 companies in 2025. Trend: 2023 $973 · 2024 $1,110 · 2025 $781
Food & beverage: $781
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 6 | $155 |
| Amgen Inc. | 6 | $126 |
| Novo Nordisk Inc | 3 | $75 |
| ANI Pharmaceuticals, Inc. | 2 | $68 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $67 |
| AstraZeneca Pharmaceuticals LP | 3 | $63 |
| Otsuka America Pharmaceutical, Inc. | 3 | $59 |
| Calliditas Therapeutics US Inc. | 2 | $47 |
| Lilly USA, LLC | 1 | $28 |
| Novartis Pharmaceuticals Corporation | 1 | $25 |
Products named: BENLYSTA, JARDIANCE, KRYSTEXXA, Ozempic, PURIFIED CORTROPHIN GEL, LOKELMA, JYNARQUE, TAVNEOS.
Industry payments across CA — which companies pay providers there.
